Abstract
Characterizing subtle cognitive changes in preclinical Alzheimer’s disease (AD) is difficult using traditional neuropsychological assessments. Remote and unsupervised digital assessments can improve scalability, measurement reliability, and ecological validity, enabling the capture of subtle changes. We evaluate such tools for use in preclinical AD, or cognitively unimpaired individuals with abnormal levels of AD pathology. We screened 1,904 reports for studies remotely assessing cognition in preclinical AD samples. Twenty-three tools were identified and their usability, reliability, and validity, including construct and criterion validity based on in-person neuropsychological and Aβ/tau measures, was reported. We present a necessary update to a rapidly evolving field, following our previous review (Öhman et al., 2021) and address open questions of feasibility and reliability of remote testing in older adults. Future applications of such tools are discussed, including longitudinal monitoring of cognition, scalable case finding, and individualized prognostics in both clinical trials and healthcare contexts.
Competing Interest Statement
SEP and FÖ declare no competing interests. JH is a paid consultant for Eisai, AlzPath, Prothena. AK is an employee of ki:elements. KVP has served as a paid consultant for Novoic, Prothena, and Biogen and is on the advisory board for Cogstate. MS has served on advisory boards for Roche and Novo Nordisk, received speaker honoraria from Bioarctic, Eisai, Genentech, Lilly, Novo Nordisk and Roche and receives research support (to the institution) from Alzpath, Bioarctic, Novo Nordisk and Roche (outside scope of submitted work); he is a co-founder and shareholder of Centile Bioscience and serves as Associate Editor with Alzheimer's Research & Therapy. DB is co-founder and shareholder of neotiv GmbH.
Funding Statement
This work was supported by the NIH/NIA (1R01AG084017-01A1). It is a part of the EU Joint Programme - Neurodegenerative Disease Research (JPND) expert group Remote Digital Assessment and Monitoring for Early Alzheimer's Disease (REMOTE-AD), which is supported by the German Federal Ministry of Education and Research (BMBF; 01ED2401) under the aegis of JPND (www.jpnd.eu).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos